A VC's time spent in industry operating roles is invaluable. It fosters empathy for the day-to-day challenges CEOs face, enabling the investor to be a more practical and effective partner, not just a source of capital or high-level advice.
Unlike tech VC, where revenue and users are key metrics, the fundamental currency for an early-stage biotech investment is clinical data. The entire investment thesis revolves around the efficiency and likelihood of translating a novel biological insight into human clinical validation.
Santé Ventures operates on the principle that a 40-50% loss ratio is inherent to early-stage biotech investing. Attempting to reduce this failure rate is seen as a sign of not taking enough risk. The core strategy is ensuring the winners are large enough to pay for all the losers.
Instead of passively evaluating deals, venture formation firms actively orchestrate new companies. They identify a proven entrepreneur they want to back, align on a thematic area, and then proactively hunt for a disruptive technology from academia to build the company around.
For companies with a core technology platform, the single most critical and common failure point is misidentifying the first clinical programs. This strategic error squanders capital and time, often proving fatal before the platform's full potential can be realized.
Funding tranches are not primarily a tool to incentivize speed. Instead, they serve as a structured 'forcing function' for the board and management to pause, review data, confirm conviction in a program, and create a natural opportunity to pivot strategy if needed.
VCs facilitate connections with potential pharma acquirers long before an exit is imminent. Pharma prefers to track a company's progress and data evolution over time. A relationship built gradually by 'following the story' is far more effective than a cold introduction at the final milestone.
The current market prefers funding drugs for clinically validated targets, reducing 'biology risk'. However, this floods popular targets with dozens of competitors, creating immense 'commercial risk' where only one or two can truly succeed in a crowded field, a potentially worse gamble.
Large pharma mergers are a net negative for biotech startups. When two giants combine, they become internally focused on integration for 2-3 years, effectively removing two active buyers from the M&A landscape and reducing exit opportunities for the entire ecosystem.